Openbookopenbook
Equity
AMLX
+0.0 · +0.00%
USD · NASDAQ

Amylyx Pharmaceuticals Inc(AMLX) Stock Analysis | Healthcare

USD --+0.00%
Reward38Moderate
Risk27Low
75%Data
Revenue down 100% YoY
Earnings Deterioration
Market Cap:3.87Bn
ⓘ
Reward Rating
38
Moderate
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
27
Low
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on AMLX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for AMLX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $42.36.

What is Amylyx Pharmaceuticals Inc?

, a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.

AMLX · Verdict

Limited reward · low risk

AMLX stands out on balance sheet and volatility, but watch the profitability signal.

Based on 88% data coverage

AMLX · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet100/100

    Current ratio 14.27

  • Volatility75/100

    Above average

  • Valuation73/100

    P/E 2.8×

Watchouts 3

  • Profitability10/100

    -75% return on equity

  • Cash flow17/100

    Weak vs peers

  • Growth31/100

    Earnings -10.0% CAGR

Model-based scoring. For information only — not financial advice.

What is Amylyx Pharmaceuticals Inc?

, a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.87B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

APNHYMid Cap / 3.7B market cap
Aspen Pharmacare Holdings Ltd ADR
Compare
DNPUFMid Cap / 4.2B market cap
Sumitomo Dainippon Pharma Co. Ltd
Compare
CRPGFMid Cap / 3.5B market cap
Integrated Cannabis Company Inc
Compare
Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Market Cap3.87B
P/E RatioN/A
Dividend YieldN/A
Beta-0.205
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
6157,783 shares
$2.1M
18,100 shares
$101k
9-12months
591,333 shares
$1.3M
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.